Immediate Impact
4 from Science/Nature 57 standout
Citing Papers
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
2022 Standout
A guide to immunotherapy for COVID-19
2022 Standout
Works of Michael White being referenced
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
2010
Function changes in spinal muscular atrophy II and III
1996
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michael White | 258 | 201 | 300 | 28 | 794 | |
| Myung Seo Kang | 222 | 158 | 160 | 40 | 807 | |
| DG Wright | 473 | 177 | 146 | 33 | 844 | |
| Elizabeth Kurczynski | 110 | 195 | 442 | 16 | 965 | |
| Denise Bonney | 158 | 151 | 92 | 41 | 853 | |
| Jennifer Stoddard | 187 | 112 | 148 | 38 | 954 | |
| BJ Bain | 129 | 61 | 294 | 26 | 935 | |
| J. M. Goldman | 60 | 119 | 187 | 30 | 746 | |
| Bruce Crooks | 119 | 340 | 259 | 36 | 747 | |
| Timothy A. Driscoll | 253 | 191 | 234 | 34 | 960 | |
| Eugene A. Cornelius | 67 | 82 | 306 | 32 | 801 |
All Works
Login with ORCID to disown or claim papers
Loading papers...